

Year in Review: Clinical Investigators Provide Perspectives on the Most Relevant New Publications, Data Sets and Advances in Targeted Therapy for Lung Cancer (Faculty Presentations)

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. Which disease-free survival result was demonstrated in the Phase III ADAURA trial evaluating osimertinib versus placebo as adjuvant therapy after complete tumor resection for patients with early-stage non-small cell lung cancer (NSCLC) with EGFR mutations?
  - a. A statistically significant and clinically meaningful benefit with adjuvant osimertinib
  - b. No statistically significant or clinically meaningful benefit with adjuvant osimertinib
  
2. Which of the following conditions has been reported as an adverse event of special interest in patients with NSCLC with HER2 mutations receiving trastuzumab deruxtecan?
  - a. New secondary cancer
  - b. Ocular toxicities
  - c. Interstitial lung disease
  
3. Which of the following drug types best describes the mechanism of action of the recently FDA-approved agent selipratinib for patients with metastatic NSCLC?
  - a. ALK inhibitor
  - b. EGFR inhibitor
  - c. HER2 inhibitor
  - d. MET inhibitor
  - e. RET inhibitor
  - f. ROS1 inhibitor
  
4. Capmatinib was recently FDA approved for patients with metastatic NSCLC with which of the following genomic alterations?
  - a. EGFR mutations
  - b. RET fusions
  - c. MET exon 14 skipping mutations